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Background: Glomerulonephritis is one of the most severe complications of lupus, a systemic disease with multi-organ
involvement, with tissue damage produced mainly by complement activation. As a result of this activation, patients with
active lupus present hypocomplementemia during disease flares, but C3 and C4 levels are recovered between episodes.
Case presentation: We present a patient who suffered two lupus nephritis episodes in 5 years, achieving complete
remission with treatment after both of them, but with C3 levels persistently below normal range. Genetic study
revealed that the patient carried a mutation in heterozygosis in the C3 gene. Serial sera samples were analyzed,
and autoantibodies to complement alternative pathway proteins (Factor I, Factor B, C3 and Properdin) were found.
Functional assays showed that these autoantibodies cause alternative pathway activation.
Conclusion: This case is the first reported of a heterozygous C3 mutation associated with lupus nephritis and
autoantibodies against complement alternative pathway proteins (Factor I, Factor B, C3 and Properdin).These
autoantibodies cause activation of this pathway and this fact could explain that the tissue damage is restricted to
the kidney.
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Lupus patients usually have low C3 and C4 levels during
disease flares because of activation of the complement
system by immune complexes (ICs) [1]. However, in
remission periods, complement levels reach normal
values. Activation of complement system by deposited
ICs cause tissue damage, but, in the other hand, compo-
nents of the classical pathway (CP) have a protective role
in facilitating the clearance of ICs and apoptotic bodies,
and their deficiency increases the risk of SLE [2,3], this
association explained not only by ICs removal from
circulation, but also by other mechanisms, including
reduction of activation thresholds of lymphocytes and
loss of self-tolerance [4,5].* Correspondence: mltrascasa@salud.madrid.org
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In 1997, a 20 year-old woman was admitted to the hospital
due to renal insufficiency and nephrotic syndrome. She
presented lower extremity oedema and high blood pres-
sure, but no articular or cutaneous manifestations.
Laboratory analysis showed serum creatinine 1.9 mg/dl,
serum albumin 2.2 g/dl and proteinuria 4.7 g/24 h with
hematuria. C3 and C4 levels were reduced (12.2 and
5.9 mg/dl, respectively), anti-nuclear and anti-DNA auto-
antibodies were positive. Other autoantibodies, including
anti-GBM and C3NeF, were negative. A renal biopsy
showed generalized and diffuse glomerular involvement,
endocapillary hypercellularity with luminal occlusion and
hyaline thrombi. Moderate mesangial proliferation in
addition to acute inflammatory infiltrate was observed.
Subendothelial deposits with wire loop images were
present. On direct immunoflourescence, irregular deposits
of C3, C1q, IgM, IgG and IgA were evident in the capillaryhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 First kidney biopsy images, and renal function and complement evolution over 7 years. A) Light microscopy showing a glomerulus
with endocapillary hipercellularity and karyorrhexis [hematoxylin-eosin (HE)], upper left panel. Light microscopy showing glomerular subendothelial
deposits with wire loops lesions (masson trichrome), upper right panel. Immunoflourescence micrograph showing granular IgG deposits in the
glomerular capillary walls, in a diffuse and global distribution, bottom left panel. Immunoflourescence micrograph showing subendothelial
deposits of C3, bottom right panel. B) Seven year evolution of C3 and C4 levels, serum creatinine and proteinuria. Arrows indicate hospitalizations and
renal biopsies due to nephrotic syndrome and renal insufficiency.
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tive, diffuse, global, proliferative glomerulonephritis class
IV-G lupus nephritis (Figure 1A).
She was treated with intravenous steroids plus oral
prednisone with progressive reduction, and cyclophos-
phamide pulses for one year, with dosage adjustments.
Renal function improved gradually, and one year after
hospitalization, the patient presented complete remis-
sion and treatment was stopped.
She remained in clinical and analytical complete
remission for five years, with the exception of C3 levels
that were persistently below the normal range. In 2003
she was hospitalized again with renal insufficiency and
nephrotic syndrome, with proteinuria 5.9 g/24 h, serum
creatinine 2.2 mg/dl, C3 10.3 and C4 1.8 mg/dl. A new
renal biopsy showed similar findings than the previous
one, with signs of chronic activity.
She recovered renal function in 5 months receiving
analogous treatment regimen as initially, with negative
proteinuria and analytical parameters normalized with
the only exception of C3 levels (evolution over 7 years is
shown in Figure 1B). Thus, C3 levels were measured in
her living family members, and her mother was found to
have reduced C3 levels too.
In 2013, under informed consent, the patient was stud-
ied in attempt to characterize possible alterations in com-
plement alternative pathway (AP), searching for either
mutations or autoantibodies that caused these decreased
serum C3 levels (methods are described in Additional file
1: Methods). The genetic study revealed that the patient
and her mother carried a mutation in heterozygosis in
exon 2 of C3 gene (c.131_146del; p.Leu44Argfs*19). This
mutation generates a premature stop, and is thought to
generate a truncated non-functional protein.
In addition to the mutation, autoantibodies against C3,
complement Factor B (FB), Properdin and Factor I (FI)
were detected in the patient’s serum, but not in her
mother. Serial sera samples were recovered and auto-
antibodies were retrospectively tested along a period of
16 years (Figure 2).
Autoantibodies to FI, C3, FB and Properdin were
detected in nearly all patient’s studied samples, as well
as significant levels of circulating complexes of IgG with
FB and Properdin (Additional file 2). During her second
hospitalization, the autoantibodies became undetectable
and remained this way for at least 4 months, probably asan effect of reduced IgG levels (440 mg/dl) due to high
proteinuria and the immunosuppressive treatment re-
ceived. After that, autoantibodies reached high titers
again, but no relapse ocurred, with only low doses of
hydroxychloroquine as treatment.
Despite carrying the same mutation that her mother,
C3 levels of the patient were always lower than hers, so
functional studies were carried out to determine whether
autoantibodies against AP proteins were responsible for
this additional C3 reduction.
Assays were designed to evaluate the capacity of these
antibodies to activate AP, both in fluid phase and on
surfaces. In AP-50 hemolytic assays, purified IgGs from
the patient reduced lysis drastically when preincubated
with NHS, but lysis was restored when more NHS was
added along with rabbit erythrocytes. This restoration
correlated with AP activation in the fluid phase, as
observed by C3 reduction when measured by nephelom-
etry following the incubation of NHS with patient’s IgG.
Nephelometric C3 and C4 measures revealed that auto-
antibodies caused a 10% reduction in C3, while main-
taining normal C4 levels for NHS. IgG purified from
pooled normal human serum had no effect on the C3
and C4 measures (data not shown). This C3 reduction
from NHS in fluid phase was analyzed by western blot,
showing proteolytic cleavage of NHS C3 induced by
patient’s IgG (Additional file 3).
These assays revealed that the autoantibodies against
AP proteins cause activation of this pathway only in
fluid phase. This fact, in addition to the C3 mutation,
may be responsible for the reduced C3 levels present in
this patient and the limited renal damage.
Conclusion
One of the main functions of complement system is
recognition and elimination of pathogens, but it is also
involved in clearance of ICs and cellular debris, in the
acquisition of self-tolerance and in modulation of the
adaptive immune response [4,6]. Complement acti-
vation mediates inflammation and tissue damage in
autoimmune diseases, but also has a protective role, as
complete deficiencies of CP components are associated
with SLE [2,3]. C3 deficiencies are extremely infrequent,
but patients usually suffer from repeated infections, and
in some cases, immune complexes-related disorders
are reported [3,6,7]. Even though SLE is an immune
Figure 2 C3 levels and autoantibodies titers follow up for a 16-year period. In A, anti-FB and anti-properdin autoantibodies are shown along
with C3 levels, and in B, anti-FI and anti-C3. Black arrows indicate hospitalizations due to renal insufficiency and the time when renal biopsies were
performed. C3 normal range: 75–150 mg/dl.
Nozal et al. BMC Nephrology  (2015) 16:40 Page 4 of 5complexes disease, its association with homozygous C3
deficiency has only been reported in 3 Japanese patients
[8], and so far, partial deficiencies of complement pro-
teins have not been associated with SLE [5,6].
Reduced C3 levels due to the mutation in this patient
could favour the appearance of autoimmunity, not only
due to C3 role in self-tolerance development, but also
because of defective immune complex clearance caused
by hypocomplementemia. Furthermore, autoantibodies
to AP proteins induce an additional reduction in serum
C3 increasing deposition of complement activation
products in renal glomeruli and contributing to local in-
flammation and tissue injury [9].
In immune complexes-mediated diseases, organ dam-
age is caused by deposition of these circulating com-
plexes and complement activation through classical
pathway. This patient’s autoantibodies recognizing AP
proteins might accumulate in the glomerulus as ICs and
activate AP locally, exacerbating renal injury and con-
tributing to disease pathogenesis.Furthermore, in this patient, complement activation
in fluid phase induced by the continuous presence of
autoantibodies against AP components may play role
in her serum complement profile with low C3 solely,
and the absence of lesions in other organs apart from
kidneys. Restricted renal damage also occurs in other
pathologies caused by deregulated systemic comple-
ment activation, such as Dense Deposit Disease.
Moreover, in a lupus nephritis model (MRL-lpr mice),
in the absence of factor H (which leads to uncon-
trolled AP activation) disease progression is acceler-
ated [10]. This outcome supports the pathogenic role
of complement AP activation in immune complex-
mediated diseases [2,10].
To our knowledge, this is the first reported case of a
heterozygous mutation in the C3 gene, clinically present-
ing as lupus nephritis, with autoantibodies against
complement alternative pathway proteins that induce
complement activation, and this fact could explain the
tissue damage is restricted to the kidneys.
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Written informed consent was obtained from the
patient for publication of this Case report and any
accompanying images. A copy of the written consent is
available for review by the Editor of this journal.
Additional files
Additional file 1: Methods.
Additional file 2: Evolution of circulating immunocomplexes of
IgG with properdin or FB and respective autoantibody titers in
the studied sera samples. Sera from 14 healthy controls were
assayed for circulating immunocomplexes, and the mean OD and
standard deviation from these samples was calculated. Arbitrary values
were assigned in relation with this calculated mean OD, considering
positive values those that were above the mean plus 2 standard
deviations from the controls.
Additional file 3: Alternative pathway activation caused by
patient’s IgG. A) Effect of IgG on total complement activity, measured
in a hemolytic AP50 assay with rabbit erythrocytes. Purified IgGs from the
patient, from pooled NHS and from a C3NeF patient (from 2 μg/μl to
0.125 μg/μl) were preincubated with NHS in a VBS-EGTA containing MgCl2
before addition of rabbit erythrocytes. B) Scheme of C3 proteolysis during
complement activation. C3 protein is composed of α and β chains. When
complement is activated, C3 convertase releases C3a from the α chain
while β chain remains intact. Subsequent proteolytic fragments of the α
chain are generated by FI to inactivate C3b. C) C3 proteolysis induced
by patient’s IgG. Purified IgG from the patient or from pooled NHS was
incubated with NHS in EDTA (no complement activation) or EGTA-Mg
buffer (alternative pathway activation), C3 cleavage in the fluid phase
was analyzed by WB. D) Quantitative analysis of C3 cleavage. C3 bands
from western-blot experiments were densitometred, and normalized using
β chain intensity. The percentage of variation between EDTA and EGTA
buffer was calculated for each band, considering EDTA samples as 100%.
The graphic represents the mean variation of intensity calculated from 6
experiments.
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